A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain
Sponsored by Janssen-Cilag Ltd.,Thailand
About this trial
Last updated 13 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Ended 19 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
* Participants whose pain has reached a stage now requiring treatment with a weak opioid, according to the opinion of treating physician
* Participants who have received a regular weak opioid, for at least 48 hours and at a dosage appropriate for their pain at that time
* Participants with a histologically, radiologically or hematologically confirmed malignancy; whose pain is judged by the investigator to be caused by the malignancy
Exclusion Criteria
* Participants who have already received regular treatment with a strong opioid for their cancer pain. This should not exceed more than 3 doses of a strong immediate release opiod in last 7 days, and none in last 24 hours
* Participants with significant abnormalities in hepatic or renal function which would in the opinion of the investigator, prevent the participants involvement in the study
* Participants with a history of allergy or hypersensitivity to tramadol or acetaminophen
* Participants who, at entry have treatments planned which may alter abruptly, the degree or nature of pain experienced (eg radiotherapy, neurological techniques surgery)
* Participants with a history of abuse of opioid analgesics prior to their diagnosis of cancer